Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 27;82(10):1694–1701. doi: 10.1054/bjoc.2000.1122

Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells

H J Chen 1, A T Treweeke 1, Y Q Ke 2, D C West 3, C H Toh 1
PMCID: PMC2374520  PMID: 10817506

Abstract

Vascular endothelial growth factor (VEGF) is one of the most potent factors for stimulating angiogenesis, an essential process required for expansion of primary tumour and dissemination of malignant cells. To investigate the possible role of VEGF in facilitating metastasis of prostate cancer via stimulating angiogenesis, we have used Northern and slot blotting, reverse transcription polymerase chain reaction, nucleotide sequence analysis and enzyme-linked immunosorbent assay to compare the VEGF expression in series of human and rat cell lines with either benign or malignant characteristics. We have also employed the chick chorioallantoic membrane (CAM) assay to measure the angiogenic activity of the VEGF derived from both benign and malignant cells. The level of VEGF mRNA expressed in the seven malignant human and rat cell lines is 3.5- to 10-fold higher than that expressed in the benign cell lines. The three metastatic variants, generated by transfection of a benign cell line with DNA extracted from prostate carcinoma cells, expressed 2.5 to 5 times more VEGF mRNA than their parental benign cells. While VEGF 121 and 165 were predominantly expressed by both the benign and malignant cells, the transcript representing VEGF 189 isoform was only detected in the malignant cells. At protein level, three human malignant cell lines produced more VEGF (2.7–7.9 ng ml−1) than the benign cell line (1.3 ng ml−1). CAM assay detected a VEGF-dependent angiogenic activity in the medium from malignant cells, but only a relatively weak VEGF-independent activity in the medium from benign cells. These results demonstrated that malignant cells did over-express VEGF and only the VEGF derived from malignant cells was angiogenically active. Thus, we suggest that the VEGF produced by malignant cells might play an important role in facilitating metastasis of prostatic cancer. © 2000 Cancer Research Campaign

Keywords: vascular endothelial growth factor, prostatic cell lines, over-expression, metastasis, isoforms

Full Text

The Full Text of this article is available as a PDF (1.8 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alwine J. C., Kemp D. J., Stark G. R. Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5350–5354. doi: 10.1073/pnas.74.12.5350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balbay M. D., Pettaway C. A., Kuniyasu H., Inoue K., Ramirez E., Li E., Fidler I. J., Dinney C. P. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res. 1999 Apr;5(4):783–789. [PubMed] [Google Scholar]
  3. Battegay E. J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl) 1995 Jul;73(7):333–346. doi: 10.1007/BF00192885. [DOI] [PubMed] [Google Scholar]
  4. Connolly J. M., Rose D. P. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol. 1998 Sep;160(3 Pt 1):932–936. doi: 10.1016/S0022-5347(01)62835-0. [DOI] [PubMed] [Google Scholar]
  5. Crew J. P., O'Brien T., Bradburn M., Fuggle S., Bicknell R., Cranston D., Harris A. L. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997 Dec 1;57(23):5281–5285. [PubMed] [Google Scholar]
  6. Cussenot O., Berthon P., Berger R., Mowszowicz I., Faille A., Hojman F., Teillac P., Le Duc A., Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J Urol. 1991 Sep;146(3):881–886. doi: 10.1016/s0022-5347(17)37953-3. [DOI] [PubMed] [Google Scholar]
  7. Cussenot O., Berthon P., Cochand-Priollet B., Maitland N. J., Le Duc A. Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res. 1994 Sep;214(1):83–92. doi: 10.1006/excr.1994.1236. [DOI] [PubMed] [Google Scholar]
  8. Deshmukh N., Scotson J., Dodson A. R., Smith P. H., Ke Y., Foster C. S. Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol. 1997 Dec;80(6):869–874. doi: 10.1046/j.1464-410x.1997.00479.x. [DOI] [PubMed] [Google Scholar]
  9. Dirix L. Y., Vermeulen P. B., Hubens G., Benoy I., Martin M., De Pooter C., Van Oosterom A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996 Oct;7(8):843–848. doi: 10.1093/oxfordjournals.annonc.a010764. [DOI] [PubMed] [Google Scholar]
  10. Dunnington D. J., Hughes C. M., Monaghan P., Rudland P. S. Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst. 1983 Dec;71(6):1227–1240. [PubMed] [Google Scholar]
  11. Duque J. L., Loughlin K. R., Adam R. M., Kantoff P. W., Zurakowski D., Freeman M. R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999 Sep;54(3):523–527. doi: 10.1016/s0090-4295(99)00167-3. [DOI] [PubMed] [Google Scholar]
  12. Ferrer F. A., Miller L. J., Andrawis R. I., Kurtzman S. H., Albertsen P. C., Laudone V. P., Kreutzer D. L. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 1998 Jan;51(1):161–167. doi: 10.1016/s0090-4295(97)00491-3. [DOI] [PubMed] [Google Scholar]
  13. Ferrer F. A., Miller L. J., Andrawis R. I., Kurtzman S. H., Albertsen P. C., Laudone V. P., Kreutzer D. L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997 Jun;157(6):2329–2333. [PubMed] [Google Scholar]
  14. Foster C. S., Abel P. D. Clinical and molecular techniques for diagnosis and monitoring of prostatic cancer. Hum Pathol. 1992 Apr;23(4):395–401. doi: 10.1016/0046-8177(92)90085-h. [DOI] [PubMed] [Google Scholar]
  15. Foster C. S. Predictive factors in prostatic hyperplasia and neoplasia. Hum Pathol. 1990 Jun;21(6):575–577. doi: 10.1016/s0046-8177(96)90001-5. [DOI] [PubMed] [Google Scholar]
  16. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E. C., Lu N., Selig M., Nielsen G., Taksir T., Jain R. K. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998 Sep 18;94(6):715–725. doi: 10.1016/s0092-8674(00)81731-6. [DOI] [PubMed] [Google Scholar]
  17. Geller J. Clinical review: 67: Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab. 1995 Mar;80(3):717–719. doi: 10.1210/jcem.80.3.7883821. [DOI] [PubMed] [Google Scholar]
  18. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  19. Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991 Dec;5(12):1806–1814. doi: 10.1210/mend-5-12-1806. [DOI] [PubMed] [Google Scholar]
  20. Häggström S., Wikström P., Bergh A., Damber J. E. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate. 1998 Jul 1;36(2):71–79. doi: 10.1002/(sici)1097-0045(19980701)36:2<71::aid-pros1>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  21. Isaacs J. T., Isaacs W. B., Feitz W. F., Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate. 1986;9(3):261–281. doi: 10.1002/pros.2990090306. [DOI] [PubMed] [Google Scholar]
  22. Jackson M. W., Bentel J. M., Tilley W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997 Jun;157(6):2323–2328. [PubMed] [Google Scholar]
  23. Kaighn M. E., Narayan K. S., Ohnuki Y., Lechner J. F., Jones L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16–23. [PubMed] [Google Scholar]
  24. Ke Y., Beesley C., Smith P., Barraclough R., Rudland P., Foster C. S. Generation of metastatic variants by transfection of a rat non-metastatic epithelial cell line with genomic DNA from rat prostatic carcinoma cells. Br J Cancer. 1998;77(2):287–296. doi: 10.1038/bjc.1998.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kraft A., Weindel K., Ochs A., Marth C., Zmija J., Schumacher P., Unger C., Marmé D., Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 1;85(1):178–187. [PubMed] [Google Scholar]
  26. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  27. Melnyk O., Zimmerman M., Kim K. J., Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol. 1999 Mar;161(3):960–963. [PubMed] [Google Scholar]
  28. Molica S., Vitelli G., Levato D., Gandolfo G. M., Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999 Dec;107(3):605–610. doi: 10.1046/j.1365-2141.1999.01752.x. [DOI] [PubMed] [Google Scholar]
  29. Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I., Keshet E., Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem. 1997 Mar 14;272(11):7151–7158. doi: 10.1074/jbc.272.11.7151. [DOI] [PubMed] [Google Scholar]
  30. Salven P., Mänpä H., Orpana A., Alitalo K., Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997 May;3(5):647–651. [PubMed] [Google Scholar]
  31. Stephan C. C., Brock T. A. Vascular endothelial growth factor, a multifunctional polypeptide. P R Health Sci J. 1996 Sep;15(3):169–178. [PubMed] [Google Scholar]
  32. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H., Paulson D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978 Mar 15;21(3):274–281. doi: 10.1002/ijc.2910210305. [DOI] [PubMed] [Google Scholar]
  33. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991 Jun 25;266(18):11947–11954. [PubMed] [Google Scholar]
  34. Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Ueyama Y., Tamaoki N. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998 Mar;77(6):998–1002. doi: 10.1038/bjc.1998.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995 Jul;147(1):9–19. [PMC free article] [PubMed] [Google Scholar]
  36. West D. C., Hampson I. N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985 Jun 14;228(4705):1324–1326. doi: 10.1126/science.2408340. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES